BMY241227P66000
- 7.75
- 0.000.00%
ブリストル・マイヤーズのニュース一覧
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Bristol Myers Squibb's Sotyktu Shows Results in Psoriatic Arthritis Trials
Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
J.P.モルガンはブリストル・マイヤーズ(BMY.US)のレーティングを強気に据え置き、目標株価を70ドルに引き上げた
J.P.モルガンのアナリストChris Schottは$Bristol-Myers Squibb(BMY.US)$のレーティングを強気に据え置き、目標株価を64ドルから70ドルに引き上げた。TipRanksのデータによると、このアナリストの最近1年間の的中率は49.1%、平均リターンは0.7%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
BioArctic Partners With Bristol Myers Squibb In Licensing Deal For PyroGlutamate-Amyloid-Beta Antibody Program
方舟健客与百时美施贵宝达成战略合作
Insitro Receives $25M In Milestone Payments From Bristol Myers Squibb For Achievement Of Discovery Milestones And Selection Of First Novel Genetic Target For ALS
Insitro Receives $25 Million in Milestone Payments From Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Urothelial Cancer Drugs Markets and Competitive Landscape Analysis, 2024-2030, Featuring Profiles of 42 Major Companies, Including AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, and Eli Lilly & Co
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Is Bristol-Myers Squibb Company (BMY) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
开启智慧医疗新篇章 | 方舟健客(06086)携手百时美施贵宝 共推行业创新发展
Bristol-Myers Squibb Shares Rise After Analyst Upgrade SAnd Positive Pipeline Outlook